Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New screening tool aims to catch hidden arthritis in psoriasis patients

NCT ID NCT06382051

Diagnosis Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 10, 2026 · Updated 7 times

Summary

This Canadian study tests whether adding two questions about morning stiffness and lower back pain to a standard screening tool (PEST) can help dermatologists identify psoriatic arthritis earlier in people with moderate-to-severe plaque psoriasis. About 502 adults who are candidates for biologic medications will complete the screening, and those flagged will see a rheumatologist for confirmation. The goal is to improve early diagnosis and prevent joint damage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PEST screening tool with two additional questions
What this could lead to
If successful, this could lead to a better screening tool that helps dermatologists identify psoriatic arthritis earlier in psoriasis patients.
What could go wrong
This is an observational study, not a treatment trial. The new screening questions may not significantly improve detection rates, and results may not apply outside Canada.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 502 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key inclusion criteria: 1. Moderate-to-severe plaque PsO patients who are candidates for bDMARDs, according to physician's clinical judgement at the time of patient enrollment. 2. Adult patients at the time of informed consent signature 3. Patients able to understand and willing to comply with protocol requirements, instructions, and restrictions 4. Residents of Canada Key exclusion criteria: 1. Patients who have previously screened positive for PsA through PEST. 2. Patients who have been diagnosed with PsA. 3. Patients who have been diagnosed with inflammatory arthritis unrelated to PsA (rheumatoid arthritis, reactive arthritis, enteropathic arthritis, axial spondyloarthritis) 4. Patients treated with a bDMARD for moderate-to-severe plaque PsO or any other medical condition within the last 6 months prior to patient enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plaque psoriasis Psoriatic arthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    30 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Calgary, Alberta, T2J 7E1, Canada

  • Novartis Investigative Site

    RECRUITING

    Edmonton, Alberta, T5J 3S9, Canada

  • Novartis Investigative Site

    RECRUITING

    Edmonton, Alberta, T6G 2C8, Canada

  • Novartis Investigative Site

    RECRUITING

    Kelowna, British Columbia, V1W 4V5, Canada

  • Novartis Investigative Site

    RECRUITING

    Surrey, British Columbia, V3R 6A7, Canada

  • Novartis Investigative Site

    RECRUITING

    Winnipeg, Manitoba, R3C 0N2, Canada

  • Novartis Investigative Site

    RECRUITING

    Fredericton, New Brunswick, E3B 1G9, Canada

  • Novartis Investigative Site

    RECRUITING

    Barrie, Ontario, L4M 6L2, Canada

  • Novartis Investigative Site

    RECRUITING

    Greater Sudbury, Ontario, P3C 1X8, Canada

  • Novartis Investigative Site

    RECRUITING

    Hamilton, Ontario, L8J 0G5, Canada

  • Novartis Investigative Site

    RECRUITING

    Hamilton, Ontario, L8N 1V6, Canada

  • Novartis Investigative Site

    RECRUITING

    Hamilton, Ontario, L8P4B4, Canada

  • Novartis Investigative Site

    RECRUITING

    London, Ontario, N6A 5R9, Canada

  • Novartis Investigative Site

    RECRUITING

    London, Ontario, N6G 0W7, Canada

  • Novartis Investigative Site

    RECRUITING

    Markham, Ontario, L3R 2C7, Canada

  • Novartis Investigative Site

    RECRUITING

    Ottawa, Ontario, K2A 3Z3, Canada

  • Novartis Investigative Site

    RECRUITING

    Richmond Hill, Ontario, L4C 9M7, Canada

  • Novartis Investigative Site

    RECRUITING

    Stoney Creek, Ontario, L8G 1H1, Canada

  • Novartis Investigative Site

    RECRUITING

    Toronto, Ontario, M4A2S8, Canada

  • Novartis Investigative Site

    RECRUITING

    Toronto, Ontario, M5S 1B6, Canada

  • Novartis Investigative Site

    RECRUITING

    Waterloo, Ontario, N2J 1C4, Canada

  • Novartis Investigative Site

    RECRUITING

    Montreal, Quebec, H1T 2M4, Canada

  • Novartis Investigative Site

    RECRUITING

    Montreal, Quebec, H1Y 3L1, Canada

  • Novartis Investigative Site

    RECRUITING

    Montreal, Quebec, H4A 3T2, Canada

  • Novartis Investigative Site

    RECRUITING

    Québec, Quebec, G1V 4X7, Canada

  • Novartis Investigative Site

    RECRUITING

    Québec, Quebec, G1W 4R4, Canada

  • Novartis Investigative Site

    RECRUITING

    Ste-Foy, Quebec, G1V 4G2, Canada

  • Novartis Investigative Site

    RECRUITING

    Verdun, Quebec, H4G 3E7, Canada

  • Novartis Investigative Site

    RECRUITING

    Saskatoon, Saskatchewan, S7K 2C1, Canada

  • Novartis Investigative Site

    RECRUITING

    Saskatoon, Saskatchewan, S7K0H6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.